Combined BCL-2 and MCL-1 inhibition also demonstrated a potent activity in Ph+ ALL xenografts, with a similar efficacy to dasatinib, a tyrosine kinase inhibitor. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.